Avecia Biotechnology, Inc./Nitto Denko Corporation: Represented Avecia, a recognized leader in the field of DNA- and RNA-based therapeutics, in its acquisition by Nitto Denko, Japan’s leading diversified materials manufacturer.
Biotie Oyj/Newron Pharmaceuticals S.p.A.: Represented Finnish biopharmaceutical company Biotie in connection with its €45 million agreement to acquire Newron, a biopharmaceutical company based in Bresso, Italy, and the subsequent successful termination of this agreement.
Clovis Oncology/Pfizer: Represented Clovis Oncology in connection with both its licensing agreement with Pfizer and a concurrent investment by Pfizer in Clovis Oncology. Under the terms of the agreement, Clovis Oncology took over responsibility for global product development and commercialization of Pfizer’s oral and IV Poly (ADP-ribose) polymerase (PARP) inhibitor, PF-01367338, for solid tumors. In addition, Pfizer Venture Investments, the venture capital arm of Pfizer, made a separate equity investment in Clovis Oncology.
Ekkio/Q-Biologicals: Represented Ekkio and its portfolio company, Amatsigroup, in the acquisition of Q-Biologicals, a leading provider of process development and biomanufacturing services.
Tikehau/Cisbio Bioassays/Abenex: Represented Tikehau on the financing aspects of the acquisition of Cisbio Bioassays by Abenex.
Valtech Cardio/HeartWare: Represented Valtech Cardio in its proposed acquisition by HeartWare, a combination that will help deliver transformative products to patients with advanced heart failure and degenerative heart conditions.
Warburg Pincus/Allos Therapeutics, Inc.: Represented Warburg as the largest selling shareholder in the $206 million sale of this biopharmaceutical developer to Spectrum Pharmaceuticals.